SCHEMBL6182474

SCHEMBL6182474

CC(CCNC(=O)c1ccc(N(C)C)cc1O)CC(=O)NCC#N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 1/20 0.42
PTGS2 P35354 1/20 0.41
APP P05067 4/20 0.38
MAOA P21397 2/20 0.36
MAOB P27338 2/20 0.36
CTSL P07711 2/20 0.33
EGLN1 Q9GZT9 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CTSB P07858 1/20 0.33
CTSS P25774 1/20 0.33
HDAC1 Q13547 4/20 0.33
HDAC10 Q969S8 4/20 0.33
HDAC6 Q9UBN7 4/20 0.33
HDAC8 Q9BY41 3/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7452250 0.83 HDAC1 (0.49) CTSLCTSBCTSSHDAC1HDAC10
SCHEMBL7449982 0.82 POLB (0.47) CTSLHDAC1MEN1NPC1ALDH1A1
SCHEMBL6196577 0.78 NPSR1 (0.38) CTSLEGLN1NPSR1CTSBCTSS
SCHEMBL7450871 0.75 ESRRG (0.48) NPC1ALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL6183716 0.74 MAPK14 (0.37) SMN1; SMN2LMNA
SCHEMBL6182469 0.73 CTSL (0.62) CTSLCTSBCTSS
SCHEMBL6182799 0.71 LMNA (0.45) CTSLCTSBCTSSHDAC1HDAC10
SCHEMBL7554411 0.71 EPHX2 (0.50) PTGS2MAOAMAOBCTSLCTSS
SCHEMBL7452326 0.71 SMN1; SMN2 (0.42) CTSLCTSBCTSSMEN1NPC1
SCHEMBL6186047 0.71 NPC1 (0.45) NPC1ALDH1A1HPGDKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1161415-B1 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2005-07-13 EP disclosed
US-6593327-B2 N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates AXYS PHARMACEUTICALS, INC. 2003-07-15 US disclosed
US-20030119788-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-06-26 US disclosed
US-6476026-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-11-05 US disclosed
EP-1161415-A2 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-12-12 EP disclosed
WO-2000055126-A2 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2000-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119788-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 KLKB1 379/4885PTGS2 1044/4885APP 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.